It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The CC chemokine receptor 6 (CCR6) is a potential target for chronic inflammatory diseases. Previously, we reported an active CCR6 structure in complex with its cognate chemokine CCL20, revealing the molecular basis of CCR6 activation. Here, we present two inactive CCR6 structures in ternary complexes with different allosteric antagonists, CCR6/SQA1/OXM1 and CCR6/SQA1/OXM2. The oxomorpholine analogues, OXM1 and OXM2 are highly selective CCR6 antagonists which bind to an extracellular pocket and disrupt the receptor activation network. An energetically favoured U-shaped conformation in solution that resembles the bound form is observed for the active analogues. SQA1 is a squaramide derivative with close-in analogues reported as antagonists of chemokine receptors including CCR6. SQA1 binds to an intracellular pocket which overlaps with the G protein site, stabilizing a closed pocket that is a hallmark of inactive GPCRs. Minimal communication between the two allosteric pockets is observed, in contrast to the prevalent allosteric cooperativity model of GPCRs. This work highlights the versatility of GPCR antagonism by small molecules, complementing previous knowledge of CCR6 activation, and sheds light on drug discovery targeting CCR6.
Small molecule antagonists of CCR6 are potential drugs for autoimmune disorders. Here the authors present inactive structures of CCR6 bound by different allosteric antagonists from two series simultaneously, offering multiple approaches to inhibit CCR6.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Pfizer Inc., Discovery Sciences, Medicine Design, Groton, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
2 Pfizer Inc., Medicine Design, Cambridge, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
3 Pfizer Inc., Inflammation and Immunology Research, Cambridge, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
4 Pfizer Inc., Medicine Design, Groton, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
5 Great Abington, Sosei Heptares, Steinmetz Building, Granta Park, Cambridge, UK (GRID:grid.410513.2); Great Abington, Nxera Pharma UK Limited, Steinmetz Building, Granta Park, Cambridge, UK (GRID:grid.410513.2)
6 Great Abington, Sosei Heptares, Steinmetz Building, Granta Park, Cambridge, UK (GRID:grid.410513.2)